Branded vs. Compounded GLP-1: Regulatory, Legal and Market Outlook

Please join Holland & Knight's Life Sciences Team and the Marwood Group for a timely webinar focused on the legal, regulatory and market dynamics shaping the branded and compounded GLP-1 landscape. Partner Michael Werner and Associate Sara Klock will lead a discussion on how compounded alternatives to branded GLP-1s such as Wegovy and Ozempic surged during recent shortages. These alternatives created new market opportunities with lower prices and more diverse distribution channels. With the GLP-1 shortage now over, our panel will examine the increased regulatory scrutiny facing compounded products, as well as implications for manufacturers, prescribers and payers as the market evolves.